Amarin Corp Plcuk (AMRN) Interest & Investment Income (2025 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Interest & Investment Income of $3.0 million for Q2 2026, up 16.41% year-over-year from $2.6 million in Q2 2025, and up 25.88% quarter-over-quarter from $2.4 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Interest & Investment Income (2025 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Interest & Investment Income for 2 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income rose 16.41% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at $11.0 million (changed N/A YoY), while the FY2025 annual figure was $10.9 million, down 19.03% from the prior year.
- Interest & Investment Income climbed to $3.0 million in Q2 2026 per AMRN's latest filing, from $2.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.0 million in Q2 2026 and bottomed at $2.4 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 219.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -679.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 80.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 77.82 Mn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Mar 31, 2026 | 2.42 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.87 Mn |